1. Bevacizumab maintenance in metastatic colorectal cancer: How long?
- Author
-
Francesca Di Pietro, Francesco Jacopo Romano, Alfonso De Stefano, Giovanni Fiore, Chiara Carlomagno, Lucia Raimondo, Stefano Pepe, Sabino De Placido, Chiara Alessandra Cella, Roberto Moretto, DE STEFANO, Alfonso, Moretto, R, Cella, Ca, Romano, Fj, Raimondo, L, Fiore, G, Di Pietro, F, Pepe, S, DE PLACIDO, Sabino, and Carlomagno, Chiara
- Subjects
medicine.medical_specialty ,treatment duration ,Bevacizumab ,Maintenance ,Metastatic colorectal cancer ,business.industry ,Colorectal cancer ,Case Report ,General Medicine ,medicine.disease ,Oxaliplatin ,Surgery ,Discontinuation ,Capecitabine ,Regimen ,Tolerability ,metastatic colorectal ,Medicine ,business ,Adverse effect ,medicine.drug - Abstract
The management of patients with non-progressive metastatic colorectal cancer after six months of treatment has not yet been codified. The most relevant concerns are the effectiveness of maintenance vs discontinuation, and the tolerability of prolonged treatment. Here we report the case of a 72-year-old man affected by colorectal cancer with lung metastases who achieved a complete response after receiving capecitabine, oxaliplatin and bevacizumab for six months, and bevacizumab alone for six months. Bevacizumab was continued as maintenance regimen for more than three years. It was discontinued because of an arthroplasty. Fifty-eight months after beginning first-line treatment, the patient remains free from relapse. Adverse effects were minimal and easily controlled.
- Published
- 2014
- Full Text
- View/download PDF